Following Baxalta Inc.'s announcement that it will hold a special meeting of stockholders on May 27 for investors to cast the final vote on its merger agreement with specialty biopharma company Shire, Scrip has taken a look back over the last year to see how this $32bn deal got made.
If you cannot view interactive content try opening this story in another browser.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?